RHRong-Xiu Huo

Rong-Xiu Huo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rong-Xiu Huo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Bangqin Wang

    Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

    1 shared publication
  • Chengcheng Wei

    Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

    1 shared publication
  • Dan-Li Meng

    Department of Rheumatology and Immunology, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

    1 shared publication
  • Danli Meng

    Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

    1 shared publication
  • Jin-Ying Lin

    Department of Rheumatology and Immunology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530016, China.

    1 shared publication
  • Jinying Lin

    Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Mortality associated with systemic lupus erythematosus combined with heart failure in the United States (1999–2020): A multiple-cause-of-death study

    by Rongxiu Huo, Chengcheng Wei, Yanting Yang, Yang Yang, Xiaocong Huo, Bangqin Wang, Danli Meng, Yijia Huang, Rongjun Huang, Jinying Lin, et al.

    This study analyzes the number of deaths related to systemic lupus erythematosus (SLE) combined with heart failure (HF) in the United States from 1999 to 2020, as well as the changing trend and causes of death of age-standardized mortality rate (ASMR). The annual number of deaths and ASMR with M32 (SLE) and I50 (HF) as the causes of death from 1999 to 2020 were extracted from the mortality database of the US CDC. Referring to the ICD-10 classification standard, the epidemiology and related data were described, and the number of deaths and the trend of ASMR were analyzed. A 2 trend test was conducted on the changing trend. Over the past 22 years, the total number of deaths related to SLE in the United States was 47,337, and the total number of deaths combined with HF was 3896, accounting for 8.2% of all deaths related to SLE. The number of male deaths from SLE combined with HF was 606 (15.6%), and that of female deaths was 3290 (84.4%), with a male-to-female ratio of approximately 1:5.4. The number of deaths related to SLE and SLE combined with HF showed an upward trend, and the difference in trend change was statistically significant (P < .001). Regarding ASMR, SLE shows a downward trend, while SLE combined with HF shows a slow upward trend. When it was regarded as MCD, both females and males showed an overall upward trend, but there was no statistically significant difference in the trend changes between the 2 groups (P = .673). The overall U/M shows a downward trend. The number of deaths in different age groups showed an upward trend, but there was no statistically significant difference in the trend changes between the 2 groups (P = .543). At present, chronic lower respiratory diseases are the leading cause of death, followed by malignant neoplasms. Although the number of deaths and ASMR in SLE combined with HF is relatively low, it shows a slow upward trend overall. Therefore, for patients with this disease, medical workers should be vigilant, provide timely diagnosis and treatment, and further reduce the mortality rate.


  • Open Access

    Short-term efficiency of plasma exchange in combination with immunosuppressants and/or biologics in the treatment of idiopathic inflammatory myopathy with rapidly progressive interstitial lung disease: a systematic review and meta-analysis

    by Yan-Ting Yang, Rong-Xiu Huo, Dan-Li Meng, Xin-Xiang Huang, Jin-Ying Lin

    Rapidly progressive interstitial lung disease (RP-ILD) is a frequent and serious manifestation of idiopathic inflammatory myopathy (IIM) associated with poor outcomes. Plasma exchange (PE) can quickly remove pathogenic substances from the blood. Therefore, PE may be efficacious in IIM patients who have elevated levels of autoantibodies, cytokines and chemokines, fighting for time for immunosuppressive therapy. However, the value of adding PE to immunosuppressants remains unclear. The purpose of this study was to determine the short-term outcomes, including the survival rate at 6 months and change of the laboratory data, of PE in combination with immunosuppressants and/or biologics in the treatment of IIM-RP-ILD. We searched PubMed, Embase and Cochrane Library to find reports of interest published from inception to March 4, 2024. STATA 15.1 was used for data analysis. A fixed or random-effects model with inverse-variance weighting was used to estimate the pooled risk ratio (RR) and 95% confidence interval (CI). Two hundred and thirty studies were identified. Eleven studies, including five retrospective cohort studies, four case-control studies and two case series, were included. PE was performed on 114 patients. The survival rate at 6 months was 80% (95%CI = 64%–92%), with moderate heterogeneity (I2=63.45%, p < 0.05). Moreover, the 6-month survival rate was significantly better in the PE group than in the non-PE group (RR, 1.34; 95% CI = 1.05–1.71, I2=30.7%; p = 0.194). ILD-related serum markers, including ferritin, KL-6 and anti-MDA-5 antibody titres, were significantly suppressed by a series of PE treatments (p < 0.05). The application of PE therapy plus treatment with corticosteroids, immunosuppressants and/or biologics was effective for patients with IIM-RP-ILD. PE may have additional supportive effect in intractable disease.